Biosimilars Would Have Reimbursement Parity With Innovators Under Health Reform Bill
This article was originally published in The Pink Sheet Daily
Executive Summary
Brand industry supports amendment in Senate Finance Committee that is sponsored by Sen. Schumer but is not as aggressive as the coding change option offered by CBO.